---
title: "Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284532331.md"
description: "Sino Biopharmaceutical (HK:1177) has announced a hybrid annual general meeting scheduled for June 17, 2025, allowing both in-person and online participation. The agenda includes reviewing the 2025 audited results, approving a final dividend, re-electing directors, re-appointing Ernst & Young as auditor, and granting authority to issue up to 20% of the company’s share capital. Analysts rate the stock as a Buy with a target price of HK$8.70. The company focuses on biopharmaceutical and chemical medicines in the healthcare sector, with a market cap of HK$99B."
datetime: "2026-04-29T09:17:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284532331.md)
  - [en](https://longbridge.com/en/news/284532331.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284532331.md)
---

# Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Sino Biopharmaceutical ( (HK:1177) ).

Sino Biopharmaceutical has called its next annual general meeting for 17 June 2025 in hybrid format, combining an in-person session in Hong Kong with an online e-voting platform to facilitate broader shareholder participation. The agenda includes receiving the 2025 audited results, approving a final dividend, re-electing directors, re-appointing Ernst & Young as auditor, and granting the board authority to issue up to 20% of the company’s share capital, measures that collectively shape governance, capital-raising flexibility and shareholder returns for the coming year.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

**More about Sino Biopharmaceutical**

Sino Biopharmaceutical Limited is a Hong Kong–listed pharmaceutical company engaged in the research, development and commercialization of biopharmaceutical and chemical medicines. The group focuses on the healthcare sector, providing a range of therapeutic products to the mainland China and broader Asian markets, and is listed on the Main Board of the Hong Kong Stock Exchange under stock code 1177.

**Average Trading Volume:** 71,429,429

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$99B

Learn more about 1177 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Got $1,000? Which of these beaten-down healthcare stocks is worth buying?](https://longbridge.com/en/news/284961286.md)
- [AimwellBio Reports Strong Early Demand From Hospital Systems and Researchers as FHIN Founding Cohort Takes Shape | AIMN Stock News](https://longbridge.com/en/news/285072004.md)
- [Clideo Introduces Advanced Online Editing Solutions to Empower Video Creators Everywhere](https://longbridge.com/en/news/284873795.md)
- [18:03 ETZibu AI Aims to Transform Patient Communication with AI-Powered Voice Agent](https://longbridge.com/en/news/285129130.md)
- [Medical Care Technologies (OTC:MDCE) Targets $100K Per Client with Real Game Used Disruptive AI Platform | MDCE Stock News](https://longbridge.com/en/news/284903395.md)